IMS Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.81M | Sell |
7,796
-694
| -8% | -$141K | 0.83% | 35 |
|
|
2025
Q2 | $1.58M | Sell |
8,490
-154
| -2% | -$28.6K | 0.74% | 39 |
|
|
2025
Q1 | $1.81M | Sell |
8,644
-9,009
| -51% | -$1.75M | 0.91% | 40 |
|
|
2024
Q4 | $3.14M | Buy |
17,653
+13
| +0.1% | +$2.39K | 1.45% | 15 |
|
|
2024
Q3 | $3.48M | Hold |
17,640
| – | – | 1.56% | 12 |
|
|
2024
Q2 | $3.46M | Sell |
17,640
-73
| -0.4% | -$12.1K | 1.61% | 11 |
|
|
2024
Q1 | $3.23M | Buy |
17,713
+73
| +0.4% | +$12.6K | 1.5% | 12 |
|
|
2023
Q4 | $2.73M | Sell |
17,640
-27
| -0.2% | -$3.94K | 1.34% | 18 |
|
|
2023
Q3 | $2.63M | Buy |
17,667
+14
| +0.1% | +$2.06K | 1.57% | 16 |
|
|
2023
Q2 | $2.38M | Buy |
17,653
+7,474
| +73% | +$1.1M | 1.32% | 19 |
|
|
2023
Q1 | $1.62M | Buy |
10,179
+148
| +1% | +$22.6K | 0.96% | 30 |
|
|
2022
Q4 | $1.62M | Sell |
10,031
-1,576
| -14% | -$242K | 1.03% | 27 |
|
|
2022
Q3 | $1.56M | Buy |
11,607
+1,728
| +17% | +$248K | 1.08% | 26 |
|
|
2022
Q2 | $1.51M | Buy |
9,879
+94
| +1% | +$14.4K | 0.98% | 24 |
|
|
2022
Q1 | $1.59M | Buy |
9,785
+11
| +0.1% | +$1.6K | 0.84% | 33 |
|
|
2021
Q4 | $1.32M | Sell |
9,774
-1,483
| -13% | -$175K | 0.68% | 42 |
|
|
2021
Q3 | $1.21M | Buy |
11,257
+809
| +8% | +$92.4K | 0.7% | 41 |
|
|
2021
Q2 | $1.18M | Buy |
10,448
+2,402
| +30% | +$271K | 0.69% | 43 |
|
|
2021
Q1 | $871K | Sell |
8,046
-8,551
| -52% | -$915K | 0.55% | 51 |
|
|
2020
Q4 | $1.78M | Buy |
16,597
+1,817
| +12% | +$175K | 1.11% | 14 |
|
|
2020
Q3 | $1.29M | Sell |
14,780
-2,380
| -14% | -$224K | 0.93% | 20 |
|
|
2020
Q2 | $1.69M | Sell |
17,160
-7,423
| -30% | -$654K | 1.31% | 12 |
|
|
2020
Q1 | $1.87M | Buy |
24,583
+4,408
| +22% | +$375K | 1.9% | 9 |
|
|
2019
Q4 | $1.79M | Sell |
20,175
-729
| -3% | -$60.5K | 1.23% | 12 |
|
|
2019
Q3 | $1.58M | Buy |
20,904
+5,279
| +34% | +$362K | 1.21% | 13 |
|
|
2019
Q2 | $1.14M | Buy |
15,625
+2,178
| +16% | +$171K | 0.84% | 31 |
|
|
2019
Q1 | $1.08M | Buy |
13,447
+24
| +0.2% | +$1.96K | 0.89% | 32 |
|
|
2018
Q4 | $1.24M | Sell |
13,423
-1,374
| -9% | -$121K | 1.16% | 19 |
|
|
2018
Q3 | $1.4M | Buy |
14,797
+143
| +1% | +$13.6K | 0.95% | 17 |
|
|
2018
Q2 | $1.36M | Buy |
14,654
+1,713
| +13% | +$167K | 0.86% | 17 |
|
|
2018
Q1 | $1.25M | Hold |
12,941
| – | – | 0.78% | 21 |
|
|
2017
Q4 | $1.25M | Sell |
12,941
-1,573
| -11% | -$148K | 0.78% | 21 |
|
|
2017
Q3 | $1.29M | Sell |
14,514
-366
| -2% | -$27.9K | 0.83% | 19 |
|
|
2017
Q2 | $1.08M | Sell |
14,880
-643
| -4% | -$43.2K | 1.02% | 29 |
|
|
2017
Q1 | $1.01M | Buy |
15,523
+786
| +5% | +$49.4K | 1.01% | 37 |
|
|
2016
Q4 | $923K | Buy |
14,737
+2,351
| +19% | +$144K | 0.99% | 41 |
|
|
2016
Q3 | $781K | Buy |
12,386
+205
| +2% | +$13.3K | 0.9% | 42 |
|
|
2016
Q2 | $754K | Sell |
12,181
-2,253
| -16% | -$137K | 0.88% | 44 |
|
|
2016
Q1 | $824K | Buy |
14,434
+3,573
| +33% | +$199K | 1% | 35 |
|
|
2015
Q4 | $643K | Buy |
10,861
+136
| +1% | +$7.83K | 0.79% | 48 |
|
|
2015
Q3 | $584K | Buy |
10,725
+1,000
| +10% | +$65.1K | 0.7% | 55 |
|
|
2015
Q2 | $653K | Buy |
9,725
+638
| +7% | +$41.7K | 0.78% | 45 |
|
|
2015
Q1 | $532K | Sell |
9,087
-4,909
| -35% | -$297K | 0.6% | 59 |
|
|
2014
Q4 | $916K | Buy |
13,996
+7,150
| +104% | +$451K | 1.05% | 25 |
|
|
2014
Q3 | $395K | Hold |
6,846
| – | – | 0.46% | 82 |
|
|
2014
Q2 | $386K | Sell |
6,846
-10,150
| -60% | -$532K | 0.42% | 84 |
|
|
2014
Q1 | $874K | Sell |
16,996
-431
| -2% | -$21.8K | 1.03% | 32 |
|
|
2013
Q4 | $920K | Buy |
+17,427
| New | +$857K | 1.16% | 21 |
|
Other funds holding ABBV
IMS Capital Management's ABBV Position: Q3 2025 in Review
IMS Capital Management reduced its AbbVie (ABBV) stake by 8.2% in Q3 2025, selling an estimated $141K and leaving 7,796 shares worth $1.81M. The position accounts for 0.83% of the portfolio, ranked #35.
IMS Capital Management first reported a position in ABBV in Q4 2013 and has held it in 48 quarters since. The position peaked at $3.48M in Q3 2024. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.
- IMS Capital Management held 7,796 shares of AbbVie worth $1.81M as of Q3 2025.
- IMS Capital Management sold 694 AbbVie shares in Q3 2025, an estimated $141K.
- AbbVie made up 0.83% of IMS Capital Management's portfolio in Q3 2025, its #35 holding.
- IMS Capital Management first reported a position in AbbVie in Q4 2013 and has held it in 48 quarters since.
- IMS Capital Management's AbbVie position peaked at $3.48M in Q3 2024.
- 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.
Based on IMS Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.